Biofrontera starts with robust growth into the new year
(Thomson Reuters ONE) -
Biofrontera AG /
Biofrontera starts with robust growth into the new year
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Preliminary Q1 numbers indicate revenue increased by 59% to over EUR 1.0m
* German revenues up 44%
* Euro 247k from EU sales outside Germany
Leverkusen, 17 April 2015 - Biofrontera AG (AIM/FSE: B8F), the biopharmaceutical
company focusing on skin cancer, has recorded robust revenue growth at the
beginning of the new fiscal year. According to preliminary numbers for the first
quarter, total revenues were more than Euro 1.0m with Euro 247k generated
outside Germany, mainly in Scandinavia and Austria. In Germany revenues
increased by 44% compared to the first quarter of the previous year and amounted
to Euro 783k.
Professor Hermann Lübbert, Chairman of the Executive Board, commented: "We are
very pleased with business development so far in the current year. We had
repeatedly emphasized that we would expect much larger revenues in 2015 and the
first quarter has fully confirmed our expectations. Growth in Germany is even
higher than anticipated. Although we do not extrapolate this growth and maintain
our guidance for the full year, this development provides us some tail wind for
the coming months."
Besides the expansion of the operational business Biofrontera's focus for this
fiscal year remains on two strategic goals: approval of our leading product
Ameluz(®) for the treatment of actinic keratosis in the USA as well as the
expansion of the approved indication to basal cell carcinoma in Europe. Both
goals should be met by 2016.
Final numbers will be announced with the Company's quarterly report on 29 May
2015.
Ends
Enquiries, please contact:
Biofrontera AG +49 (0) 214 87 63 2 0
Prof. Hermann Lübbert, Chief Executive Officer press(at)biofrontera.com
Thomas Schaffer, Chief Financial Officer www.biofrontera.com
IR Germany: Brainwell Asset Solutions +49 (0) 152 08931514
Jürgen Benker
Nomad and Broker: Shore Capital +44(0) 20 7408 4090
Bidhi Bhoma / Toby Gibbs
IR UK: Seton Services +44(0) 20 7603 6797
Toni Vallen
Financial PR: Gable Communications +44(0) 20 7193 7463
John Bick +44 (0)7872 061007
Background:
The Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical
company specialising in the development, sale and distribution of drugs and
medical cosmetics for the care and treatment of skin diseases. Biofrontera's
most important product is Ameluz(®), a prescription drug which is approved in
Europe for the treatment of mild and moderate actinic keratosis (superficial
skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first
German pharmaceutical start-up company to obtain centralised approval for a drug
it has developed itself. The company also plans for Ameluz(®) to be approved for
basal cell carcinoma and is currently preparing for approval in other countries,
especially in the largest pharmaceutical market in the world, the United States.
The company also markets the Belixos(®) dermatological range of cosmetics.
Belixos(®) products contain combinations of active substances extracted from
plants, relieve itching and redness and are used for the regenerative care of
chronic skin conditions such as atopic dermatitis or psoriasis. At the moment,
Belixos(®) cream, gel and scalp tonic are available through Amazon.
The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the
Chairman of the company's Management Board, and has its headquarters in
Leverkusen, Germany.
www.biofrontera.com
This communication expressly or implicitly contains certain forward-looking
statements concerning the business activities of Biofrontera AG. These forward-
looking statements reflect the opinion of Biofrontera at the time of this
communication and involve certain known and unknown risks. The actual results
achieved by Biofrontera may differ significantly from future results or
performances which are published in its forward-looking statements. Biofrontera
assumes no responsibility to update its forward-looking statements.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via GlobeNewswire
[HUG#1911993]
Unternehmensinformation / Kurzprofil:
Datum: 17.04.2015 - 08:00 Uhr
Sprache: Deutsch
News-ID 386530
Anzahl Zeichen: 5514
contact information:
Town:
Leverkusen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 180 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biofrontera starts with robust growth into the new year"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
